The Tumor Vaccine Group is a group of multidisciplinary investigators who work to support a comprehensive research effort for evaluating the role of the immune system in modulating cancer and develop novel therapies that will impact the lives of people with the disease. The overall goals of the program are to define cancer-immune interactions that will result in the development diagnostic, preventative, and treatment strategies to combat cancers.
Cancer VaccinesTVG aims to develop a multi-antigen cancer vaccine targeting immunogenic overexpressed self-proteins that are biologically relevant to the growth of a cancer cell and are involved in the malignant transformation.
Cancer DiagnosticsTVG is able to detect very early tumors and premalignant lesions by looking for an antibody immune response to cancer, not looking for proteins secreted by cancer.
Immunologic Monitoring Laboratory (IML)TVG is working to develop immunologic correlates of cancer vaccine efficacy, i.e. measure the generation of a cancer antigen specific immunity after active immunization and correlate that measurement to clinical outcome.
Adoptive T Cell TherapyTVG uses adoptive T cell therapy to augment T cell responses over and above that achievable by vaccination alone.
Tumor Immune EnvironmentsTVG is evaluating multiple strategies that could be used alone or in combination with other immune based therapies to modulate the immunosuppressive tumor microenvironment.
Research FundingResearch Grants that support TVG research. We remain committed to using every research dollar effectively to translate our basic research findings into clinical trials for people living with cancer. Continuity of funding is an ongoing challenge that we meet with creativity and commitment every day.